title: Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
abstract: Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.
authors.affiliation: Division of Oncology, Rambam Health Care Campus, POB 9602, 31096 Haifa, Israel.
authors.forename: Orit
authors.initials: O
authors.lastname: Kaidar-Person
authors.forename: Salem
authors.initials: S
authors.lastname: Billan
authors.forename: Abraham
authors.initials: A
authors.lastname: Kuten
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D017239:Paclitaxel / Q000008:administration & dosage; D049268:Positron-Emission Tomography; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016190:Carboplatin; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab